Immunic, Inc. (IMUX) vs The Joint Corp. (JYNT)
A side-by-side comparison of Immunic, Inc. and The Joint Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMUX
Immunic, Inc.
$7.80HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT
JYNT
The Joint Corp.
$7.11HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — IMUX vs JYNT
growth of $100 · dividends reinvested · last 10yIMUX -99.7% (-43.5%/yr)JYNT +195.9% (+11.5%/yr)JYNT compounded faster over this window
Log scale — wide-divergence pair
IMUX JYNT
IMUX vs JYNT: by the numbers
- •IMUX is the larger company ($106M vs $101M market cap).
- •JYNT is profitable (6.49% net margin) while IMUX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | IMUX | JYNT |
|---|---|---|
| P/E ratio | N/A | 26.80 |
| Forward P/E | N/A | 29.60 |
| P/S ratio | N/A | 1.73 |
| P/B ratio | 0.83 | 6.39 |
| EV / EBITDA | N/A | 25.68 |
| FCF yield | N/A | 4.17% |
Profitability
| Metric | IMUX | JYNT |
|---|---|---|
| Gross margin | 0.00% | 81.08% |
| Operating margin | 0.00% | 2.45% |
| Net margin | 0.00% | 6.49% |
| ROE | -87.45% | 23.96% |
| ROIC | -92.16% | 5.11% |
Growth (annualized)
| Metric | IMUX | JYNT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -3.57% |
| EPS CAGR (5Y) | N/A | -27.37% |
| FCF CAGR (5Y) | N/A | -16.35% |
| Total return CAGR (5Y) | -35.70% | -40.34% |
Frequently asked
- Is IMUX or JYNT more profitable?
- JYNT runs the higher net margin — IMUX at 0.00% versus JYNT at 6.49%.
- How have IMUX and JYNT total returns compared?
- Over the past 10 years, IMUX delivered -43.80% and JYNT delivered 11.23% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Joint P/E ratioImmunic ROEJoint ROEImmunic operating marginJoint operating marginImmunic revenue growthJoint revenue growthImmunic free cash flowJoint free cash flow
Immunic & Joint appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.